Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jan;11(Suppl 1):S57-S64.
doi: 10.21037/jtd.2018.11.85.

The challenges of evaluating predictive biomarkers using small biopsy tissue samples and liquid biopsies from non-small cell lung cancer patients

Paul Hofman  1   2   3
Affiliations
Review

The challenges of evaluating predictive biomarkers using small biopsy tissue samples and liquid biopsies from non-small cell lung cancer patients

Paul Hofman. J Thorac Dis. 2019 Jan.

Abstract

The list of theranostic biomarkers for the care of patients with advanced stage or metastatic non-small cell lung cancer has lengthened considerably these last few years. Moreover, the advances in therapeutics will certainly increase the number and complexity of these tests performed in laboratories in the near future. In addition, the methods for investigation of biomarkers that require access to biological tissue are less and less invasive with the consequential increase in the use of small-sized tissue biopsies and cytological and blood samples. Thus, each laboratory must master the management of the biological samples according to the number and type of tests to be performed. This review will provide an update of the difference challenges facing pathologists and biologist in responding to the issues related to new treatments. These challenges concern: (I) the management of the pre-analytical phase; (II) the appropriate choice of the technological approach; (III) the performance of quality control; (IV) the mastering of the delay in obtaining the results; and (V) the economic model of the laboratory.

Keywords: Therapeutic strategy; biological samples; challenge; innovation; theranostic biomarkers.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: P Hofman declares receiving honoraria from pharmaceutical (Astrazeneca, Roche, Novartis, Bristol Myers Squibb, MSD) and biotechnology (Qiagen, Biocartis, Thermofisher) companies for attendance at advisory board meetings.

References

    1. Absenger G, Terzic J, Bezan A. ASCO update: lung cancer. Memo 2017;10:224-7. 10.1007/s12254-017-0373-x - DOI - PMC - PubMed
    1. Le-Rademacher J, Dahlberg S, Lee JJ, et al. Biomarker Clinical Trials in Lung Cancer: Design, Logistics, Challenges, and Practical Considerations. J Thorac Oncol 2018;13:1625-37. 10.1016/j.jtho.2018.08.2019 - DOI - PubMed
    1. VanderLaan PA, Rangachari D, Majid A, et al. Tumor biomarker testing in non-small-cell lung cancer: A decade of change. Lung Cancer 2018;116:90-5. 10.1016/j.lungcan.2018.01.002 - DOI - PMC - PubMed
    1. Rolfo C, Mack PC, Scagliotti GV, et al. Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC. J Thorac Oncol 2018;13:1248-68. 10.1016/j.jtho.2018.05.030 - DOI - PubMed
    1. Roy-Chowdhuri S, Chen H, Singh RR, et al. Concurrent fine needle aspirations and core needle biopsies: a comparative study of substrates for next-generation sequencing in solid organ malignancies. Mod Pathol 2017;30:499-508. 10.1038/modpathol.2016.228 - DOI - PubMed